Inactive Instrument

Other languages RayzeBio, Inc.

Equities

RYZB

US75525N1072

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Bristol-Myers Squibb Completes RayzeBio Acquisition	Feb. 26
Bristol Myers : acquisition de RayzeBio finalisée	Feb. 26
Rayzebio, Inc. Announces Executive Changes	Feb. 26
Bristol-Myers Squibb Company completed the acquisition of RayzeBio, Inc..	Feb. 25
Wall Street : dans le vert après un jeudi euphorique	Feb. 23
Bristol Myers Squibb Says RayzeBio Shareholders Overwhelmingly Accept $4.1 Billion Buyout Offer	Feb. 23
Wall Street : stabilisation en vue après un jeudi euphorique	Feb. 23
Bristol Myers : succès de l'OPA sur RayzeBio	Feb. 23
Bristol Myers Squibb Reportedly Eyeing $13 Billion from Bond Sale Launched Wednesday	Feb. 14
Bristol-Myers Squibb, RayzeBio Say Hart-Scott-Rodino Act Waiting Period Expires	Feb. 12
Bristol Myers : expiration de la période HSR pour RayzeBio	Feb. 12
Bristol-Myers Squibb's New Product Performance Mixed as Headwinds Persist, Morgan Stanley Says	Feb. 05
Bristol Myers posts better-than-expected 4th-quarter results	Feb. 02
Bristol-Myers Squibb Plans 16 New Products by 2030, CEO says	Jan. 08
Bristol Myers expects to launch 16 new products through 2030 - CEO	Jan. 08
Fusion Pharmaceuticals an 'Attractive' Takeover Target Following Recent Radiopharma Deals, Oppenheimer Says	Dec. 27
Bristol-Myers Squibb's RayzeBio Deal Validates Value of SSTR2, Lung Cancer, B. Riley Says	Dec. 27
Fusion Pharmaceuticals 'Last Available Target' With Solid Supply Chain After Point Biopharma, RayzeBio Takeovers, Oppenheimer Says	Dec. 27
Vorsichtig aufwärts bei dünnen Umsätzen	Dec. 27
Vorsichtig aufwärts bei dünnen Umsätzen	Dec. 27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages RayzeBio, Inc.

Equities

RYZB

US75525N1072

Other languages

Filters